Table 3.

Multivariable analysis of the association between minimum ALC and OM (n = 747)

HR (95% CI)
Minimum ALC0.23 (0.16–0.35)
Neoadjuvant/adjuvant chemotherapy use (vs. none)0.53 (0.34–0.84)
Radiotherapy use (vs. none)0.75 (0.54–1.03)
Neighborhood socioeoconomic status (vs. 1 = lowest)0.85 (0.74–0.97)
NH Black (vs. NH white)1.72 (0.91–3.24)
NH Asian (vs. NH white)0.98 (0.62–1.54)
Hispanic (vs. NH white)1.29 (0.75–2.23)
Positive for deleterious mutation in BRCA1/2 (vs. negative/VUS)0.87 (0.40–1.91)
Untested for deleterious mutation in BRCA1/2 (vs. negative/VUS)1.45 (0.91–2.32)
Age at diagnosis (per year)1.01 (1.00–1.03)
Ever neutropenic (ANC <1 K/μL) (vs. never neutropenic)1.06 (0.72–1.55)
Stage II (vs. stage I)1.47 (0.97–2.23)
Stage III (vs. stage I)4.25 (2.69–6.74)
Grade 2 (vs. grade 1)2.58 (0.60–11.05)
Grade 3 (vs. grade 1)3.82 (0.93–15.72)
Unknown grade (vs. grade 1)2.18 (0.46–10.35)
  • NOTE: Statistically significant variables are in bold font.